Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation

Constipation Clinical Trial

Official title:

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RM-131 Administered to Patients With Chronic Constipation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01781104
• Other study ID #: RM-131-006
• Status: Completed
• Phase: Phase 2
• First received: January 28, 2013
• Last updated: September 21, 2016
• Start date: March 2013
• Est. completion date: October 2014

Study information

• Verified date: September 2016
• Source: Motus Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate safety and tolerability as well as the effects of RM-131 on colonic transit, bowel consistency, bowel habits, abdominal pain, and other abdominal symptoms in patients with chronic constipation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: October 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria

• Able to provide written informed consent prior to any study procedures, and willing and able to comply with study procedures.

• Diagnosis of chronic IDIOPATHIC constipation, including experiencing constipation for 12 or more weeks in the preceding 12 months (defined by Rome III criteria for Functional Constipation, but all patients must meet the modified criterion of a history of =4 average defecations per week)

• Stable concomitant medications (no changes in regimen for at least 2 weeks prior to baseline period)

• Body mass index of 18-40 kg/m2

• Females must not be lactating or pregnant

Exclusion criteria

• Unable/unwilling to provide informed consent or to comply with study procedures

• Diagnosis of secondary constipation e.g. underlying general neurological disease such as Parkinsonism, multiple sclerosis, diseases associated with peripheral neuropathy, iatrogenic constipation

• Structural or metabolic diseases that affect the GI system NOTE: Patients with clinical suspicion of upper or lower GI obstruction must have been evaluated per standard of care and obstruction ruled out before screening

• Unable to withdraw the following medications 48 hours prior to baseline period and throughout the study (except as protocol defined rescue medications):

• Medications that alter GI transit including laxatives, magnesium and aluminum containing antacids, prokinetics, erythromycin, narcotics, anti-cholinergics, tricyclic antidepressants, SNRI and newer antidepressants

• Selective serotonin reuptake inhibitor (SSRI) antidepressants are permissible at low, stable doses

• Analgesic drugs including opiates, NSAIDs and COX-2 inhibitors

• GABAnergic agents

• Benzodiazepines

• NOTE: stable doses of thyroid replacement, estrogen replacement, low dose aspirin for cardioprotection, and birth control (but with adequate backup contraception as drug-interactions with birth control have not been conducted) are permissible

• Drugs with a low therapeutic index, such as warfarin, digoxin, anti-seizure medications

• History of surgery within 60 days of screening

• Acute or chronic illness or history of illness, which in the opinion of Investigator, could pose threat/harm to the patient or obscure interpretation of laboratory test results or interpretation of study data such as frequent angina, Class III or IV congestive heart failure, moderate impairment of renal or hepatic function, poorly controlled diabetes, etc

• History of hypersensitivity to mannitol (an ingredient of both active and placebo study medications)

• Clinically significant abnormalities on screening laboratories or physical examination as determined by Investigator

• Abnormal 12-lead electrocardiogram (ECG), including evidence of acute myocardial or subendocardial ischemia and clinically significant arrhythmias or conduction abnormalities (including prolonged QTc > 500 msec) or abnormal blood pressure at screening except minor deviations deemed to be of no clinical significance by Investigator

• Acute GI illness within 48 hours of initiation of the baseline period

• ALT or AST > 1.2 X upper limit of normal during screening

• Females who are pregnant or breastfeeding

• History of excessive alcohol use or substance abuse

• Participation in an investigational clinical study within 30 days prior to dosing in the present study

• Any other reason, which in the opinion of the Investigator, would confound proper interpretation of the study

Exclusion criteria at the end of the baseline period

• In addition, patients will not be randomized into the double-blind treatment comparison if during the baseline period they:

• used rescue medications such as laxatives, beyond those allowed by protocol

• demonstrated lack of compliance

• averaged more than 4 spontaneous bowel movements per week

• Substudy patients only: did not demonstrate slow colonic transit at end of baseline period (GC 24 >2.4)

• Women of child-bearing potential: positive pregnancy test

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Constipation

Intervention

Drug:
• RM-131
Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
• Placebo
Placebo delivered subcutaneously once daily for 14 days.

Locations

Country	Name	City	State
United States	Mayo Clinic Florida	Jacksonville	Florida
United States	Mayo Clinic Rochester	Rochester	Minnesota
United States	Mayo Clinic Arizona	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Motus Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of RM-131 on colonic transit	Change from baseline colonic geometric center at 24 hours	End of 14 day Baseline and end of 14 day Treatment periods	No
Secondary	Safety and tolerability of RM-131	Assessment of adverse events and clinical laboratory evaluations	Duration of the study, an expected average of 9 weeks	Yes
Secondary	Effect of RM-131 on stool consistency	Change in responses on Bowel Habit Diary Cards	Daily for the duration of the study, an expected average of 9 weeks	No